Patents Assigned to ZymoGenetics
  • Soluble zalpha11 cytokine receptors
    Patent number: 7189695
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zlapha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: March 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Julia E. Novak, James W. West, Richard D. Holly, Andrew J. Nelson
  • Isolated polynucleotides encoding a human cytokine receptor human cytokine receptor
    Patent number: 7189839
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: March 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Method for treating inflammation
    Patent number: 7189394
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: March 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Donald C. Foster, Wenfeng Xu, Hal Blumberg, Yasmin A. Chandrasekher
  • secretory signal
    Patent number: 7189835
    Abstract: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: March 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Michael R. Stamm
  • IL-21 antagonists
    Patent number: 7186805
    Abstract: The polypeptides, and the polynucleotides encoding for them, described herein are IL-21 antagonists that bind with specificity and exhibit an EC50 that is not detectable in receptor binding studies. These molecules have mutations in the D helix of the IL-21 molecule, and can be used to inhibit the activity of IL-21 with its cognate receptor.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: March 6, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, James W. West, Julia E. Novak
  • Kunitz domain polypeptide zkun10
    Patent number: 7183391
    Abstract: We claim the proteinase inhibitors comprising a Kunitz domain, wherein the Kunitz domain comprises amino acid residues 57–107 of SEQ ID NO: 2. We also claim a fusion protein comprising said Kunitz domain. In addition, we claim a method of inhibiting protease degradation or protease activity in a composition which contains plasma proteins and proteases. The proteinase inhibitors is used as components of cell culture media in cell culture process, and as inhibitors of protease-mediated degradation of plasma proteins in protein purification.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: February 27, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox
  • Methods of using human Zven proteins
    Patent number: 7179787
    Abstract: The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1–3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: February 20, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Method of treating fibroproliferative disorders
    Patent number: 7172757
    Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: February 6, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Adipocyte complement related protein ZACRP3X2
    Patent number: 7169897
    Abstract: Novel zacrp3x2 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp3x2 protein or fragments thereof.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: January 30, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Betty A. Haldeman, Edward C. Thayer, Paul O. Sheppard
  • Use of blood coagulation factor XIII for treating hemophilia A
    Publication number: 20070021340
    Abstract: A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.
    Type: Application
    Filed: September 20, 2006
    Publication date: January 25, 2007
    Applicant: ZymoGenetics Inc.
    Inventors: Jan Ohrstrom, Paul Bishop, Lynn Rose
  • Method for treating hemophilia B
    Publication number: 20070015709
    Abstract: Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX.
    Type: Application
    Filed: September 15, 2006
    Publication date: January 18, 2007
    Applicant: ZymoGenetics Inc.
    Inventors: Jan Ohrstrom, Lynn Rose, Paul Bishop
  • Homogeneous preparations of IL-28 and IL-29
    Patent number: 7157559
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: January 2, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Method for inhibiting the formation of seromas using factor XIII
    Patent number: 7153830
    Abstract: Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: December 26, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul D. Bishop, Angelika Grossman
  • Mammalian cytokine-like factor 7
    Patent number: 7153937
    Abstract: Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: December 26, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Teresa Gilbert, Theresa Martinez, Ross C. Hoffman
  • Antibody to mammalian cytokine-like polypeptide-10
    Patent number: 7151166
    Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: December 19, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Betty A. Haldeman
  • Methods for reducing TGF-? production and for promoting repair of liver damage
    Patent number: 7147852
    Abstract: Materials and methods for reducing TGF-? production and promoting repair of liver damage in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of an anti-zvegf3 antibody in combination with a pharmaceutically acceptable delivery vehicle.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: December 12, 2006
    Assignee: ZymoGenetics, Inc.
    Inventor: Debra G. Gilbertson
  • Polynucleotides encoding disintegrin homologs, and related products
    Patent number: 7135317
    Abstract: The present invention relates to human polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the zdint1 polypeptides.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: November 14, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Nand Baindur, Theresa A. Deisher, Paul D. Bishop
  • Methods of use of FGF homologs
    Patent number: 7135459
    Abstract: The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: November 14, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin
  • Methods for treating viral infection using IL-28 and IL-29
    Patent number: 7135170
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: November 14, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson
  • Cell surface display of proteins by recombinant host cells
    Patent number: 7125973
    Abstract: Methods and vectors are described for expressing recombinant proteins on the surface of host cells. These processes and compositions provide the basis for strategies to produce a fusion protein, comprising a membrane anchor that allows extracellular attachment of the fusion protein in a type II orientation.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: October 24, 2006
    Assignee: ZymoGenetics, Inc.
    Inventor: Si Lok